A 23% reduction in major adverse cardiovascular events, observed across pooled Phase 3 data, is exactly the kind of number that transforms a cholesterol drug from a niche add-on into a serious commercial contender. NewAmsterdam Pharma reported second-quarter results on August 5th against a backdrop of accelerating regulatory and clinical momentum for obicetrapib, its oral CETP inhibitor, with the European pathway now largely cleared and the pivotal outcomes data on the horizon.
The headline is a positive CHMP opinion recommending marketing authorization for both obicetrapib monotherapy and the obicetrapib/ezetimibe fixed-dose combination under the brand names Ubeslo and Evlarco, covering primary hypercholesterolemia and mixed dyslipidemia including heterozygous familial hypercholesterolemia. The standard European Commission review runs approximately 67 days after a CHMP opinion, meaning a formal EU authorization is realistically weeks away. That approval would give NewAmsterdam a commercial foothold before the PREVAIL cardiovascular outcomes trial delivers its interim read, a sequencing that matters enormously for payer negotiations and prescriber confidence.
The PREVAIL interim analysis is planned for Q4 2026, with results expected in Q1 2027. That trial, enrolling over 9,500 patients with established ASCVD on maximally tolerated lipid-lowering therapy, is registered as NCT05202509 and carries the weight of a full cardiovascular outcomes designation. The pooled mediation analysis presented at NLA added interpretive texture: LDL-C lowering drove most of the observed MACE benefit, with lipoprotein(a) reduction as a meaningful secondary contributor accounting for the remainder of that 84.5% combined mediation figure. That framing matters because it positions obicetrapib’s Lp(a)-lowering effect not as an isolated novelty but as a quantifiable, additive mechanism. Separately, four analyses presented at AAIC showed statistically significant reductions in plasma p-tau217, pushing the company closer to formally initiating an Alzheimer’s prevention trial later this year. The RUBENS Phase 3, targeting patients with type 2 diabetes or metabolic syndrome, is expected to report topline data before year-end, adding a third indication thread to the program.
NewAmsterdam held $678.3 million in cash at June 30th, a runway that covers the PREVAIL readout without obvious financing pressure. The single metric worth watching now is the PREVAIL interim result: if it crosses the pre-specified efficacy threshold, it validates the mediation data already in hand and makes the European launch commercially irreversible rather than speculative.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
CHMP Recommends Marketing Authorization for Obicetrapib in EU
3 weeks ago[…] European commercialization rights and is responsible for all regional regulatory interactions. NewAmsterdam collects tiered royalties in the low double-digits to mid-twenties on net sales, plus up to an […]
Comments are closed.